Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 2/20 | 0.31 |
| ▸ | ADH1C | P00326 | 2/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH7 | P40394 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | ADH4 | P08319 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31076221 | 0.95 | TSHR (0.35) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL9173367 | 0.93 | CETP (0.33) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL22098328 | 0.93 | TSHR (0.36) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL6898635 | 0.90 | — | — | |
| SCHEMBL2236262 | 0.86 | TSHR (0.34) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL1633195 | 0.85 | — | — | |
| SCHEMBL11503129 | 0.85 | TSHR (0.38) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL9646862 | 0.85 | TSHR (0.38) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL3193317 | 0.83 | TSHR (0.39) | TSHRADH1BADH1CADH1AADH7 | |
| SCHEMBL3963526 | 0.81 | TSHR (0.42) | TSHRADH1BADH1CADH1AADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1458679-B1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7635713-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2009-12-22 | — | — | US | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-15 | — | — | US | disclosed |
| US-7335680-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2008-02-26 | — | — | US | disclosed |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| EP-1458679-A2 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053923-A2 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | TSHR 3433/4885ADH1B 1109/4885ADH1C 159/4885 |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | PGF, PTGIS, PTGIR | TSHR 3698/4885ADH1B 981/4885ADH1C 223/4885 |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | TSHR 3433/4885ADH1B 1109/4885ADH1C 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.